724 related articles for article (PubMed ID: 20471669)
21. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
22. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
23. Altered plasma fibrin clot properties are associated with in-stent thrombosis.
Undas A; Zalewski J; Krochin M; Siudak Z; Sadowski M; Pregowski J; Dudek D; Janion M; Witkowski A; Zmudka K
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):276-82. PubMed ID: 19910643
[TBL] [Abstract][Full Text] [Related]
24. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
25. A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
Gaussem P; Gandrille S; Molho-Sabatier P; Capron L; Fiessinger JN; Aiach M
Thromb Haemost; 1990 Feb; 63(1):76-81. PubMed ID: 2111050
[TBL] [Abstract][Full Text] [Related]
26. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
27. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
28. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
29. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
[TBL] [Abstract][Full Text] [Related]
30. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit.
Undas A; Slowik A; Wolkow P; Szczudlik A; Tracz W
Thromb Res; 2010 Apr; 125(4):357-61. PubMed ID: 19942259
[TBL] [Abstract][Full Text] [Related]
31. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
Stepień E; Plicner D; Kapelak B; Wypasek E; Sadowski J; Undas A
Kardiol Pol; 2009 Aug; 67(8A):947-55. PubMed ID: 19784898
[TBL] [Abstract][Full Text] [Related]
32. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
33. Acute CO poisoning is associated with impaired fibrinolysis and increased thrombin generation.
Gawlikowski T; Gomolka E; Piekoszewski W; Jawień W; Undas A
Basic Clin Pharmacol Toxicol; 2013 May; 112(5):352-6. PubMed ID: 23228150
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
35. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
36. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
37. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
38. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
39. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy.
Nastałek M; Wojas-Pelc A; Undas A
J Thromb Thrombolysis; 2010 Aug; 30(2):121-6. PubMed ID: 20419337
[TBL] [Abstract][Full Text] [Related]
40. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]